Evidence map›Paper›PMID 40080155›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Exploring mechanisms of britannin against colorectal cancer based on experimentally validated network pharmacology.

Xiaoli Liu, Qiuxia Ye, Mengdi Hao, Huimin Li, Dajin Yuan, Wenbin Huang, Wenjie Li, Lei Ding

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoli LiuDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Qiuxia YeDepartment of Liver Vascular Disease Diagnosis and Treatment Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Mengdi HaoDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Huimin LiDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Dajin YuanDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Wenbin HuangDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Wenjie LiDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Lei DingDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China. dinglei1005@126.com.

Funding

National Natural Science Foundation of China 82170525
6 · The paper itself

Abstract

Britannin is an active compound derived from Inula japonica Thunb. that possess a wide range of pharmacological activities. However, the mechanism underlying its influence on colorectal cancer (CRC) is not clear. This study aimed to explore the mechanism of britannin in treating colorectal cancer. We employed network pharmacology and single-cell RNA sequencing to assess the potential mechanism of britannin in CRC therapy. In vivo and in vitro experiments were conducted to confirm the effect of britannin on CRC cells and tumor environment. Network pharmacology analysis identified 36 britannin-related genes associated with CRC. Key signaling pathways, including the PI3K-Akt pathway, PD-L1 expression, and HIF-1 signaling, were implicated in britannin's anti-CRC effects. CIBERSORT and scRNA-seq analyses revealed that britannin affects tumor cells, macrophages, and endothelial cells, with a particular impact on macrophage polarization. In vitro assays confirmed that britannin suppressed CRC cell proliferation, promoted apoptosis, and inhibited AKT phosphorylation. In vivo, britannin significantly suppressed tumor growth and modulated the tumor microenvironment by inhibiting M1 macrophage polarization. Britannin may inhibit colorectal by directly inhibiting colon cancer cells and modulating macrophage polarization.

Indexed as

Antineoplastic Agents, PhytogenicColorectal NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceMice, Inbred BALB CMice, NudeNetwork PharmacologyProto-Oncogene Proteins c-aktSignal TransductionTumor MicroenvironmentXenograft Model Antitumor AssaysAntineoplastic Agents, PhytogenicProto-Oncogene Proteins c-aktBritanninColorectal cancerMacrophage polarizationNetwork pharmacology

Identifiers

PMID40080155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.